Metformin also has indirect antitumoral effects due to its ability to reduce insulin and insulin-like growth factor 1 (IGF-1) levels and to influence metabolic pathways such as lipid metabolism and inflammation [15], which are known to promote HCC tumour growth and proliferation [162,163,164,165]. The gene discussed is IGF1; the disease is neoplasm.